Strides Arcolab, a Rs 725-crore plus Bangalore-based pharma giant, has received two ANDA approvals for Dexamethasone injection USP, 4mg/ml, and Dexamethasone Sodium Phosphate injection USP, 10 mg/ml.

The products are licensed to Akorn-Strides, LLC, which is a joint venture that was formed in 2004 by Akron Inc and Strides Arcolab. Ravi Seth, CEO – international operations of Strides, said, "We are pleased to announce that the Akorn Strides partnership has now received eleven ANDA approvals of the 18 filed till date and commercialization in case of some of these products has already commenced effective Q3, 2008."

Strides manufacture pharmaceuticals formulations in various dosage forms, including capsules, tablets, and liquid injectables and is one of the world's top five manufacturers of softgel capsules. It has a major presence in developed markets such as the US, Canada and part of Europe and in various developing countries such as Africa, Latin America and Asia.